The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Vertex Pharmaceuticals

  • VRTX
  • NASDAQ
  • Consumer Products
  • Latest 63.25
  • Currency US$
  • Change 0.81
  • Percent Change 1.297 %
  • Volume 1,886,008
  • Tue Apr 15, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 62.83
  • Previous Close 62.44
  • High 63.97
  • Low 59.79
  • Bidx1 57.14
  • Askx1 85.00
  • 52-week High07/19 89.96
  • 52-week Low04/18 51.96
  • Beta 0.261
  • Market Cap 14,785.32M
  • EPS -2.04
  • P/E
  • Forward P/E 91.67
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $1,211,980,000
  • Earnings $-445,040,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $569,290,000
  • Current Ratio 3.99

12 months ended Dec 31, 2013.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $2,319,040,000
  • Liabilities $962,630,000
  • Liabilities-to-Equity Ratio 0.71

Price Ratios

  • Price to Sales 12.20
  • Price to Book 10.90
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Jan 29 $-0.57 May 1 $-0.79
Surprises Jan 29 15.79% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Apr 16, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)

Related Securities
Symbol Type Latest % Chg

Officers

  • Jeffrey M. Leiden Chairman of the Board; Preside
  • Ian F. Smith Executive Vice President and C
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

50 NORTHERN AVENUE
BOSTON, MA
02210

Phone: (617)-341-6393
Fax: (617)-5762109

investorinfo@vrtx.com
www.vrtx.com

Ideas & Discussion

Live Discussion of VRTX on StockTwits